1. Adelaide Research & Scholarship
  2. Schools and Disciplines
  3. School of Medicine
  4. Medicine
  5. Medicine publications
Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/9567
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPan, B.-
dc.contributor.authorFarrugia, A.-
dc.contributor.authorTo, L.-
dc.contributor.authorFindlay, D.-
dc.contributor.authorGreen, J.-
dc.contributor.authorLynch, K.-
dc.contributor.authorZannettino, A.-
dc.date.issued2004-
dc.identifier.citationJournal of Bone and Mineral Research, 2004; 19(1):147-154-
dc.identifier.issn0884-0431-
dc.identifier.issn1523-4681-
dc.identifier.urihttp://hdl.handle.net/2440/9567-
dc.description© American Society for Bone and Mineral Research.-
dc.description.abstractBisphosphonates are used to prevent osteoclast-mediated bone loss. Zoledronic acid inhibits osteoclast maturation indirectly by increasing OPG protein secretion and decreasing transmembrane RANKL expression in human osteoblasts. The decreased transmembrane RANKL expression seems to be related to the upregulation of the RANKL sheddase, TACE.-
dc.description.statementofresponsibilityBeiqing Pan, Amanda N Farrugia, Luen Bik To, David M Findlay, Jonathan Green, Kevin Lynch, Andrew CW Zannettino-
dc.language.isoen-
dc.publisherAmer Soc Bone & Mineral Res-
dc.source.urihttp://dx.doi.org/10.1359/jbmr.2004.19.1.147-
dc.subjectCells, Cultured-
dc.subjectOsteoblasts-
dc.subjectHumans-
dc.subjectHydroxamic Acids-
dc.subjectDiphosphonates-
dc.subjectImidazoles-
dc.subjectMetalloendopeptidases-
dc.subjectCarrier Proteins-
dc.subjectMembrane Glycoproteins-
dc.subjectReceptors, Tumor Necrosis Factor-
dc.subjectBlotting, Western-
dc.subjectFlow Cytometry-
dc.subjectImmunohistochemistry-
dc.subjectGene Expression-
dc.subjectADAM Proteins-
dc.subjectRANK Ligand-
dc.subjectReceptor Activator of Nuclear Factor-kappa B-
dc.subjectOsteoprotegerin-
dc.subjectADAM17 Protein-
dc.subjectZoledronic Acid-
dc.titleThe nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)-
dc.typeJournal article-
dc.identifier.doi10.1359/jbmr.2004.19.1.147-
pubs.publication-statusPublished-
dc.identifier.orcidZannettino, A. [0000-0002-6646-6167]-
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.